An Open-Label, Phase 1/2 Study on safety and effectiveness of RAD001 in Subjects with Myelofibrosis sponsored by Associazione italiana del Farmaco (AIFA).
Phase of Trial: Phase I/II
Latest Information Update: 22 Jun 2016
At a glance
- Drugs Everolimus (Primary)
- Indications Myelofibrosis
- Focus Adverse reactions; Biomarker
- 25 May 2011 Status changed from recruiting to completed as reported by Australian New Zealand Clinical Trials Registry.
- 15 May 2009 New trial record